Claro Advisors LLC Makes New $297,000 Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

Claro Advisors LLC purchased a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the fourth quarter, Holdings Channel reports. The fund purchased 4,757 shares of the company’s stock, valued at approximately $297,000.

A number of other large investors have also bought and sold shares of TMDX. USA Financial Formulas purchased a new position in TransMedics Group in the 3rd quarter worth approximately $55,000. Quarry LP raised its holdings in shares of TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares in the last quarter. National Bank of Canada FI raised its holdings in shares of TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after acquiring an additional 262 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after acquiring an additional 316 shares in the last quarter. Finally, Rakuten Securities Inc. bought a new position in shares of TransMedics Group during the third quarter valued at approximately $126,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Price Performance

TMDX opened at $62.54 on Wednesday. TransMedics Group, Inc. has a 12-month low of $58.27 and a 12-month high of $177.37. The company has a market cap of $2.10 billion, a price-to-earnings ratio of 66.53 and a beta of 2.12. The stock has a fifty day simple moving average of $73.15 and a two-hundred day simple moving average of $119.58. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the prior year, the company posted ($0.12) earnings per share. The company’s revenue was up 63.7% on a year-over-year basis. Research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In related news, Director Edward M. Basile sold 6,750 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the sale, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

TMDX has been the subject of a number of recent analyst reports. Piper Sandler decreased their target price on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, December 11th. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Canaccord Genuity Group decreased their target price on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Finally, TD Cowen decreased their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.